Bharat V, Das N K, Mohanty B, Jha A C, Chawla S C, Dash B, Mohanty R
Department of Cardiology, Tata Main Hospital, Jamshedpur, India.
J Heart Valve Dis. 2003 May;12(3):362-9.
Patients with mechanical heart valves implanted at four cardiothoracic centers were followed up in a hospital in Eastern India. Despite successful surgery and regular hospital visits, long-term survival was compromised by anticoagulation-related complications.
Systematic analysis revealed under-anticoagulation in most patients. Thrombosis risk in 80 patients on regular follow up from 1989 to 1997 was 8.68 per 100 patient years (pt-yr). The incidence of both thrombotic and bleeding complications was reported as less than two per 100 pt-yr, when prothrombin time was consistently in the range of INR 2.5 to 3.9. In targeting this low event rate, impediments to optimum anticoagulation in the local set-up were identified. International Normalized Ratio (INR) was introduced to report prothrombin time (PT). Patients and doctors were educated about drug and diet interactions with oral anticoagulants (OAC) and the early features of valve thrombosis. Treatment protocols were evolved. The impact of the remedial measures was studied in 81 patients (64 old, 17 new) over a total of 254 pt-yr of follow up, from 1998 to 2001.
Thrombosis risk was reduced from 8.68 to 5.12 per 100 pt-yr, while non-fatal bleeding events increased from 0.28 to 1.96 per 100 pt-yr. Due to early recognition of occlusive prosthetic valve thrombosis and institution of fibrinolytic therapy, fatal events were reduced from 3.8 per 100 pt-yr to none for four consecutive years (statistically significant at 99% CI).
The clinical audit proved to be a valuable tool for understanding the problems in health care delivery, and bringing about improvement.
在印度东部的一家医院对四个心胸外科中心植入机械心脏瓣膜的患者进行了随访。尽管手术成功且定期到医院就诊,但抗凝相关并发症影响了患者的长期生存。
系统分析显示大多数患者存在抗凝不足的情况。1989年至1997年对80例定期随访患者的血栓形成风险为每100患者年8.68例(患者-年)。当凝血酶原时间持续处于国际标准化比值(INR)2.5至3.9范围内时,血栓形成和出血并发症的发生率均报告为每100患者-年少于2例。为实现这一低事件发生率,确定了当地最佳抗凝治疗的障碍。引入国际标准化比值(INR)来报告凝血酶原时间(PT)。对患者和医生进行了关于口服抗凝剂(OAC)的药物和饮食相互作用以及瓣膜血栓形成早期特征的教育。制定了治疗方案。在1998年至2001年共254患者-年的随访中,对81例患者(64例为老患者,17例为新患者)研究了补救措施的影响。
血栓形成风险从每100患者-年8.68例降至5.12例,而非致命性出血事件从每100患者-年0.28例增加至1.96例。由于早期识别出人工瓣膜闭塞性血栓形成并采用了溶栓治疗,致命事件从每100患者-年3.8例降至连续四年无致命事件发生(在99%置信区间具有统计学意义)。
临床审计被证明是了解医疗保健提供中的问题并实现改进的宝贵工具。